LFMD vs DBVT vs HIMS vs ALKS

For growth investors, Hims & Hers Health, Inc.

(HIMS) is the stronger pick with 59. 0% revenue growth year-over-year, versus -8. 7% for LifeMD, Inc. (LFMD). Alkermes plc (ALKS) offers the better valuation at 24. 5x trailing P/E, making it the more compelling value choice. Analysts rate LifeMD, Inc. (LFMD) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Alkermes plc (ALKS) is the cheapest at 24.

5x versus Hims & Hers Health, Inc. at 55. 4x.

Over the past 5 years, Hims & Hers Health, Inc.

(HIMS) delivered a total return of +173. 9%, compared to -68. 3% for DBV Technologies S. A. (DBVT). Over 10 years, the gap is even starker: LFMD returned +241. 4% versus DBVT's -87. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Alkermes plc (ALKS) is the lower-risk stock at 1.

00β versus Hims & Hers Health, Inc. 's 2. 48β — meaning HIMS is approximately 149% more volatile than ALKS relative to the S&P 500. On balance sheet safety, Alkermes plc (ALKS) carries a lower debt/equity ratio of 4% versus 2% for Hims & Hers Health, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Hims & Hers Health, Inc.

(HIMS) is pulling ahead at 59. 0% versus -8. 7% for LifeMD, Inc. (LFMD). On earnings-per-share growth, the picture is similar: LifeMD, Inc. grew EPS 56. 6% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Over a 3-year CAGR, HIMS leads at 64. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Alkermes plc (ALKS) is the more profitable company, earning 16.

4% net margin versus -3. 7% for LifeMD, Inc. — meaning it keeps 16. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALKS leads at 17. 2% versus -4. 0% for LFMD. At the gross margin level — before operating expenses — ALKS leads at 86. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for DBVT: 134.

8% to $46. 33.

In this comparison, LFMD (1.

4% yield) pays a dividend. DBVT, HIMS, ALKS do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Alkermes plc (ALKS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.

00)). Hims & Hers Health, Inc. (HIMS) carries a higher beta of 2. 48 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ALKS: -12. 0%, HIMS: +188. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: LFMD is a small-cap quality compounder stock; DBVT is a mega-cap quality compounder stock; HIMS is a small-cap high-growth stock; ALKS is a small-cap quality compounder stock. LFMD pays a dividend while DBVT, HIMS, ALKS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.